In November, Vertex submitted an application to the European Medicines Agency EMA to extend the use of Kaftrio to people with specific mutations beyond F508del, aged 2 years and older. Until now, Kaftrio had only been approved and reimbursed for people with at least one F508del mutation, but this extension would also make people with […]
Month: December 2023
CF Europe’s Urgent Fundraising Campaign: Bringing Hope to People with Cystic Fibrosis in Gaza
Amid conflict and chaos, people living with very vulnerable health conditions, including those with cystic fibrosis (CF) in Gaza face additional challenges and are in desperate need of food, water and medication. The health of people with CF and other respiratory diseases are doubly impacted by fumes and dust resulting from bombardments. CF Europe is […]
Why does the reform of the EU Pharmaceutical Legislation matter for people with CF?
Cystic Fibrosis Europe (CF Europe) is committed to advancing the interests and well-being of people with cystic fibrosis (CF) across Europe. As advocates for the CF community, we recognize the importance of collective efforts in shaping the future of pharmaceutical legislation within the European Union (EU). In line with the recommendations put forth by EURORDIS […]